SCHEMBL16990

SCHEMBL16990

O=S(=O)(c1ccccc1)c1ccc(-c2ccc(O)cn2)cc1Cl

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 2/20 0.44
GAA P10253 1/20 0.44
GFER P55789 1/20 0.44
RXFP1 Q9HBX9 1/20 0.42
AURKA O14965 3/20 0.41
ABCC9 O60706 1/20 0.40
ABCC8 Q09428 1/20 0.40
KCNJ11 Q14654 1/20 0.40
KCNJ8 Q15842 1/20 0.40
KMO O15229 2/20 0.39
HSD11B1 P28845 1/20 0.39
ALOX5AP P20292 1/20 0.38
FEN1 P39748 1/20 0.38
HSD17B1 P14061 1/20 0.38
HSD17B2 P37059 1/20 0.38
LMNA P02545 2/20 0.38
KMT2A Q03164 1/20 0.38
NPSR1 Q6W5P4 1/20 0.38
ALDH1A1 P00352 1/20 0.38
MAPT P10636 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16663 0.85 RXFP1 (0.42) RXFP1AURKAABCC9ABCC8KCNJ11
SCHEMBL17437 0.82 POLB (0.53) POLBGAAGFERABCC9ABCC8
SCHEMBL16281 0.79 HSD11B1 (0.61) ABCC9ABCC8KCNJ11KCNJ8HSD11B1
SCHEMBL12078980 0.79 HSD11B1 (0.61) ABCC9ABCC8KCNJ11KCNJ8HSD11B1
SCHEMBL16736 0.79 HSD11B1 (0.61) ABCC9ABCC8KCNJ11KCNJ8HSD11B1
SCHEMBL8866123 0.70 HSD11B1 (0.57) POLBGAAGFERABCC9ABCC8
SCHEMBL1992954 0.69 POLB (0.44) POLBGAAGFERABCC9ABCC8
SCHEMBL10454872 0.69 POLB (0.59) POLBGAAGFERHSD11B1LMNA
SCHEMBL2462163 0.69 KIF18A (0.61) POLBGAAGFERABCC9ABCC8
SCHEMBL18573277 0.69 MMP3 (0.56) HSD17B1HSD17B2KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120225854-A1 COMPOUNDS THAT INTERACT WITH GLUCOKINASE REGULATORY PROTEIN FOR THE TREATMENT OF DIABETES AMGEN INC. (US) 2012-09-06 US disclosed
WO-2012027261-A1 SULFONYLPIPERAZINE DERIVATIVES THAT INTERACT WITH GLUCOKINASE REGULATORY PROTEIN FOR THE TREATMENT OF DIABETES AMGEN INC. (US) 2012-03-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120225854-A1 COMPOUNDS THAT INTERACT WITH GLUCOKINASE REGULATORY PROTEIN FOR THE TREATMENT OF DIABETES GCKR, GCK, SLC5A2 POLB 4613/4885GAA 455/4885GFER 3327/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.